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Background:  Contrast media induce vascular dysfunction, and are associated with reduction of nitric oxide bioavailability and nephropathy. 
This study compares the effect of Ioxilan 350 versus Iodixanol 320 on vascular dysfunction, image quality and contrast resolution, and patient 
satisfaction.
Methods:  In this trial, 132 consecutive subjects (age 60±5 years, 60% male, were randomized to either Ioxilan or Iodixanol, and underwent non-
enhanced and enhanced computed tomography (CT). Contrast induced vascular dysfunction was calculated as: the difference in cross sectional 
area (CSA) of ascending aorta (AA) before and after contrast-injection (CSA AA enhanced - CSA AA non-enhanced). The image quality of 15 coronary-
segments was graded by two-cardiologists with the use of a four-point scale (1=excellent to 4=poor-enhancement). Contrast-resolution was assessed 
by measuring: 1) signal-attenuation from pulmonary artery (PA) to AA during timing bolus phase, and 2) signal to noise ratio in AA and ventricular 
cavity based on Hounsfield unit. Patient satisfaction was assessed based on flushing sensation, injection site pain/warmth, headache, nausea and 
allergic reactions (each 2 point).
Results:  There were no significant differences between Ioxilan and Iodixanol in age, gender and risk factors (p>0.05). Contrast induced vascular 
dysfunction was significantly less with Ioxilan compared to Iodixanol; in which the risk of vascular dysfunction was 3.59 (95%CI 1.99-6.48, p=0.004) 
folds less in Ioxilan compared to Iodixanol. Signal-attenuation was 138% less in Ioxilan (15±5%) than Iodixanol (35±8%) (likelihood ratio: 2.38, 
95%CI 1.87-2.72,p=0.001). Similarly, signal to noise ratio was 68% higher in Ioxilan as compared to Iodixanol (p=0.009). Both contrasts have a 
comparable image quality (94% in Ioxilan vs. 85% in Iodixanol, p=0.2). Finally, patient satisfaction rate was 33.3% higher with Ioxilan (90%) as 
compared to Iodixanol (69%)(p=0.001).
Conclusion:  Ioxilan contrast agent was associated: 1) less contrast induced vascular dysfunction, and 2) improved contrast resolution and image 
quality as well as patient satisfaction, as compared to Iodixanol.
